THERAMetrics is an international, technology-driven discovery and development group focused on providing an innovative approach to Clinical Research through our Drug Repositioning and Repurposing system (DRR 2.0) and integrated Clinical Development Services (iCDS).
Through our unique DRR software tool we support customers in de-risking and renovating their drug discovery pipeline, addressing new therapeutics areas and optimizing IP protection decisions.
THERAMetrics is a full-service TCRDO (Technology-driven Contract Research & Development Organization including cGMP IMP Services) providing technological services and solutions to innovative biopharmaceutical companies throughout the entire drug discovery & development cycle – from Preclinical to Market Access.
The Investigational Medicinal Products ("IMPs") include contract IMP manufacture and IMP logistics tailored to meet the specific requirements of Phase I-IV clinical trials.
The subsidiary Pierrel Research IMP Services ,approved by the European Medical Agency, provides high quality Investigational Medicinal Product (IMP) services for international clinical trials.
THERAMetrics has developed a valuable portfolio of patents and Orphan Drug Designations and is seeking opportunities for licensing out some of its projects and for joining partnerships for drug development.
DRR 2.0 is THERAMetrics' biomathematical platform for drug repositioning and repurposing through which it has obtained its patent portfolio.
With its innovative methodology, DRR 2.0 enables THERAMetrics to offer consultancy and partnerships to biotech and pharma companies for the development of new projects.
Therametrics provides full clinical research and scientific marketing services as well as of clinical trial services for research and development of new molecules and drug products to the pharmaceutical, biotechnology and healthcare industries.
The services provided include clinical trials application and management, e-Clinical Trial Technology, Pharmacovigilance and Drug Safety, Regulatory Services, Data Management & Statistical Evaluation and Medical Writing;
Stans, Switzerland, December 03, 2014
THERAMetrics holding AG (SIX: TMX) and Centurion Pharma negotiating Final agreement for collaboration in the rare diseases area
Following the press release of the 4th August 2014 regarding the signing of the Term Sheet, THERAMetrics holding AG and Centurion Pharma have announced today that they are currently finalizing discussions with the aim to sign the Final agreement...
Stans, Switzerland, November 17, 2014
THERAMetrics holding AG (SIX: TMX) appoints Dr. Marco Grenningloh as Managing Director of its German-controlled Pierrel Research Europe GmbH
THERAMetrics (SIX: TMX, "THERAMetrics" or the "Group") announces that effective today Dr. Marco Grenningloh will be appointed as new Chief Operative Officer of THERAMetrics Group and the new Managing Director...
Stans, Switzerland, November 13, 2014
THERAMetrics holding AG (SIX: TMX) announces the financial results for the quarter and nine months ended September 30, 2014.
For the quarter ended September 30, 2014 the Group generated revenues of EUR 3.5 million and EBITDA of negative EUR 1.9 million.